UBS Global Life Sciences Conference. September 26, 2006
|
|
- Rudolf Lawrence
- 6 years ago
- Views:
Transcription
1 UBS Global Life Sciences Conference September 26, 2006
2 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Act ) that involve a number of risks and uncertainties. These forward-looking statements include statements relating to: the Company s future growth, Pharmaceutical industry growth and increases in clinical trials being conducted, the Company expanding its client base, the Company leveraging its existing relationships, leveraging the strong reputation of PharmaNet, the proposed amendment of the credit facility, 2006 guidance and financial metrics, the Company s ability to increase its client penetration for bioanalytical services, the Company s ability to recruit subjects, the impact of discontinued operations in Miami and Ft. Myers, Canadian tax credits, industry trends, the globalization of clinical trials, cross-selling opportunities, and regulatory changes. Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forwardlooking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, our ability to leverage the strong reputation of PharmaNet, whether adverse publicity relating to PDGI s Miami operations causes clients to select competitors, not only for early stage branded clinical trials but also for other aspects of PDGI s business; PDGI s ability to resolve open issues relating to its Miami property including whether it can successfully appeal and/or enjoin the Miami-Dade County Unsafe Structures Board ruling and any related fines or expenses if we are unsuccessful, the associated costs and expenses with discontinuing the Company s operations in Miami and Ft. Myers, whether a building permit will be issued, whether PDGI will prevail in the pending land lease litigation; continued adverse publicity related to actions of the United States Senate Finance Committee; developments with respect to the SEC s inquiry and securities class action lawsuits and derivative lawsuits; PDGI s assessment of its current FDA inspections; PDGI s ability to successfully achieve and manage the technical requirements of specialized clinical trial services, while complying with applicable rules and regulations; regulatory changes; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; PDGI's ability to compete internationally in attracting clients in order to develop additional business; cancellation of contracts; PDGI s ability to retain and recruit new employees; PDGI's clients' ability to provide the drugs and medical devices used in its clinical trials; PDGI s future stock price; PDGI s financial guidance; and the national and international economic climate as it affects drug development operations. Further information can be found in PDGI's risk factors contained in its Form 10-K filed as the Company s former name, SFBC International, Inc., with the SEC in 2006 and other filings with the Securities and Exchange Commission. We do undertake to update these forward-looking statements, and you are urged to read our filings with the Securities and Exchange Commission.
3 Overview Well Positioned in the Rapidly Growing CRO Industry Diverse Client Base Branded pharmaceutical, biotechnology, generic drug and medical device companies Experienced Management Team Global Operations Strategic locations accommodate complex global programs Strong Clinical Development Expertise in all Therapeutic Areas Focus on attractive, high growth fields From study design to phase I-IV Advanced Technology Platforms PharmaSoft Information Technology State-of-the-art bioanalytical laboratories Financial Strength Cash, cash equivalents and investments in marketable securities of approximately $59.6 million at June 30, 2006
4 Clinical Development of Pharmaceuticals IND submitted NDA submitted Drug discovery Pre-clinical Clinical trials FDA Review Large scale manufacturing/phase lv Phase I healthy volunteers Phase li patients Phase lil patients Phase IV Post marketing & generics COMPOUNDS 250 COMPOUNDS 5 COMPOUNDS 1 FDA Approved Compound PharmaNet Clinical Development, Software and Consulting Services 5 years 1.5 years 6 years 2 years 2 years Synthesis 11.0% Screening Testing 15.5% Toxicology 4.9% Dosage formulation 8.0% Clinical evaluation Phase l lll 32.0% Process Development 9.1% Regulatory Process 4.5% Other 2.0% Clinical evaluation Phase lv 12.9% ~$1 billion to get a new drug to market Pharma R&D Budget Allocation Sources: Pharma.org, Business Insights Interactive: The Pharmaceutical Market Outlook through 2005.
5 Well Positioned in the Rapidly Growing CRO Industry Broader acceptance Outsourcing of drug development services continues to grow $10 Billion market growing 14-16% (1) R&D Results Successes are increasing the number of compounds in the development pipeline Breadth and depth of clinical trials expanding Increasing complexity and globalization of clinical trials driving demand for global CROs with expertise, experience, technical skills and scale Biotechnology benefiting from the R&D expenditure growth combined with further development progress before partnering Increased focus and requirements for post-marketing studies Proven track record of success CROs have demonstrated that they can perform drug development faster and more cost-effectively (1)
6 Diverse Client Base Clinical Mix Client Mix Geographic Mix Early stage Generic Large Pharma Europe ROW USA Late stage Biotech Medium Pharma Canada 2006E Revenue: $281 $290 Million Balanced clinical mix and geographic distribution of clients
7 Experienced Management Team Johane Boucher-Champagne, DSA Ian Holmes, PhD EVP, Early Clinical Development and COO of Anapharm PharmaNet SVP, Corporate Development James P. Burns, Jr., PhD Mary F. Johnson, PhD PharmaNet SVP, Regulatory Consulting Worldwide PharmaNet SVP, Biostatistics Mark Di Ianni Michael E. Laird, RPh EVP, Strategic Initiatives PharmaNet VP, Worldwide Business Development Pablo Fernandez, FFPM Sean P. Larkin PharmaNet SVP, Medical Affairs PharmaNet EVP, Late Phase Development Steven A. George Marc LeBel, PharmD PharmaNet SVP, Information Technology, Worldwide EVP Bioanalytical Laboratories, CEO and President of Anapharm Dalvir Gill, PhD David Natan PharmaNet EVP, US Clinical Research EVP, Reporting and Analysis, Chief Accounting Officer Jack W. Green, PhD Thomas J. Newman, MD PharmaNet SVP, Data Management EVP, Late Stage Development and COO PharmaNet John P. Hamill Robert Reekie, FFPM EVP and CFO PharmaNet EVP, Operations, Europe and Asia-Pacific Gregory M. Hockel, MBA, PhD Robin C. Sheldrick PharmaNet SVP, Regulatory Affairs Worldwide PharmaNet VP, Human Resources
8 Client Service Worldwide: 2,000+ Employees, 30+ Offices, 26 Countries, 5 Continents Clinical Facilities Bioanalytical Laboratories PharmaNet PharmaNet Field-Based Staff Locations Field-Based Staff Amersfoort, NETHERLANDS Bangalore, INDIA Barcelona, SPAIN Blue Bell, PA, USA Boston, MA, USA Buenos Aires, ARGENTINA Charlotte, NC, USA Chicago, IL, USA Frankfurt, GERMANY High Wycombe, UK Kennett Square, PA, USA London, ON, CANADA Madrid, SPAIN Montreal, QC, CANADA Moscow, RUSSIA Mumbai, INDIA Munich, GERMANY Paris, FRANCE Philadelphia, PA, USA Princeton, NJ, USA (2) Quebec City, QC, CANADA Research Triangle Park, NC, USA San Diego, CA, USA Singapore Stockholm, SWEDEN Sydney, AUSTRALIA Toronto, ON, CANADA (2) Trois-Rivieres, QC, CANADA Warsaw, POLAND Washington, DC, USA Wilmington, DE, USA Zurich, SWITZERLAND Belgium Brazil Canada Chile Czech Republic Hong Kong Hungary Indonesia Ireland Israel Italy Japan Korea Mexico Peru Shanghai South Africa Taiwan United States * As of June 2006
9 Strong Clinical Development Expertise: Therapeutic Divisions Medical Expertise (Strategy) Operational Expertise (Implementation) Oncology Neuroscience Cardiovascular Infectious disease Experience and capabilities in high-growth therapeutic areas
10 Industry-leading Research, Technology and Consulting Services Throughout the Clinical Development Process Volunteer recruitment Protocol development Site management and monitoring Phase I IV studies Bioequivalence trials Project management Patient recruitment Clinical laboratory Sample analysis Discovery Method development and validation Biomarkers Stability evaluation Documentation Submission QA/QC Safety/pharmacovigilance Scientific and medical writing Advisory/safety committee participation Data management Biostatistics SAS programming PK/PD modeling Efficacy, toxicity, dosage-optimization, market expansion, and agency-mandated studies Regulatory Statistical Promotional assistance Clinical
11 Services and Expertise: Core Services Phase I Clinical Development Services Facilities in Québec City (168 beds) and Montréal, Canada (150 beds) Bioanalytical Laboratory Services Quantitative determination of drugs and/or metabolites in biological matrices such as blood, serum, plasma, or urine Labs in Princeton, NJ; Philadelphia, PA; Québec City and Toronto, Canada; and Barcelona, Spain Supports preclinical, bioavailability and drug metabolism, bioequivalence, Phase I IV and drug interaction studies
12 Services and Expertise: Core Services Late Clinical Development A complete range of services for drug development and registration Phases II, III, and IV clinical development services Data Management Biostatistics Regulatory Affairs Medical Affairs Safety Reporting Electronic Submissions Web-based technologies Experience in essentially all significant therapeutic areas being pursued by the pharmaceutical industry
13 Services and Expertise: Core Services Post Marketing (Phase IIIb-IV) Dedicated professionals with extensive product-development experience in Phase IIIb IV studies Specialists designing and executing programs that meet the highest standards of scientific integrity and regulatory compliance, while meeting commercial objectives Scientific and medical staff work with client teams to extend patent protection and develop: New indications New formulations Line extensions New dosages New strategies to compete with newly introduced products Rx to OTC switches Reinvigoration of aging brands Enhancing commercial value through scientific expertise
14 Services and Expertise: Consulting Dedicated regulatory professionals with international productdevelopment expertise, including senior-level FDA officials from: Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiologic Health (CDRH) Value added services Clinical development plans and strategies cgmp compliance plans In-licensing evaluations New product due diligence Risk/benefit analysis Best practice assessments Combination product evaluations Assistance with preparation of CMC section Medical and regulatory assessments Evaluation of pre-clinical data for acceptability
15 Services and Expertise: PharmaSoft IT PharmaSoft electronic data capture (EDC) and data management system employed in >50% late stage studies initiated in 2006 Facsimile data capture system with interactive character recognition (ICR) Interactive voice response system (IVRS) Serious adverse event system Project management information system Easy to use, web-based, 21 CFR Part 11 compliant, efficient
16 2006 Strategic Priorities Early Stage Restore early stage business to historical levels of performance Optimize mix of generic and branded business Enhance Phase I capabilities in Montreal Assess opportunities for cost reductions and operational efficiencies Leverage custom assay development expertise New early stage headquarters in Quebec City and associated sale lease-back agreement Timing of Phase I facility in Toronto Closing activities in preparation of sale of Florida facilities
17 2006 Strategic Priorities Late Stage Increase penetration of existing client base and expand client base to drive organic growth Leverage strong development expertise in virtually every therapeutic area with focus on oncology, neurosciences, cardiovascular and infectious diseases Geographic expansion in Asia, Latin America, Central and Eastern Europe Build or buy assessments of complementary services at optimal time Medical Imaging Clinical trial materials management Central laboratory services targeted at niche applications Leverage PharmaSoft IT platform with enhanced marketing investment and/or partnership
18 2006 Strategic Priorities Corporate and Financial Add members to the Board of Directors Amend credit facility Sale lease-back of Quebec City facility
19 How we differentiate PharmaNet Development Group Proven medical, scientific and regulatory expertise in key therapeutic areas around the world Strong project management personnel and tools PharmaSoft Unparalleled client service Dedicated to patient safety
20 Investment Summary Well Positioned in the CRO Industry Diverse Client Base Experienced Management Team Dedicated to patient safety Global Operations Strong Clinical Development Expertise Advanced Technology Platforms Financial Strength Unparalleled client service
21 UBS Global Life Sciences Conference September 26, 2006
Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationBiotherapeutic product characterization to support accelerated process development
Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals 2015 Biomanufacturing Technology Summit June 25, 2015 Our Mission: Treating
More informationIntellectual Capital. On Demand.
Intellectual Capital. On Demand. A unique approach to consulting. RGP is made up of proven problem solvers accomplished professionals who give you the help you need, when you need it, how you need it.
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationA drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationSAMPLE. Bracco Imaging S.p.A.Market Share Analysis. Bracco Imaging S.p.A. Market Share Analysis GDME0639CDB / Published January 2013
Market Share Analysis Reference Code: GDME0639CDB Publication Date: January 2013 GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page 1 Table
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationINO Therapeutics is now
INO Therapeutics is now The materials contained herein are a description of our business. They do not purport to be all inclusive or contain all information that you desire. This document includes or may
More informationGLOBAL VIDEO-ON- DEMAND (VOD)
GLOBAL VIDEO-ON- DEMAND (VOD) HOW WORLDWIDE VIEWING HABITS ARE CHANGING IN THE EVOLVING MEDIA LANDSCAPE MARCH 2016 A CHANGING VIDEO-VIEWING LANDSCAPE Nearly two-thirds of global respondents say they watch
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationRunning an RTB Network Across 10 Markets Publisher Opportunities ATTILA BARTA
Running an RTB Network Across 10 Markets Publisher Opportunities ATTILA BARTA Head Cadreon PROGRAMMATIC ADVERTISING THE SELLERS PERSPECTIVE The Strengths, Weaknesses, Opportunities and the Pitfalls for
More informationESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,
More informationSiemens Partner Program
Siemens Partner Program Factory Automation Partner Strategy for Factory Automation End Customer Focus on core competencies Demand on efficient solutions Certified Partner Added value in solutions and services
More informationHealthcare.
Healthcare www.stantonchase.com Stanton Chase is a leader in executive search and leadership consulting with a global footprint, local expertise, and extensive experience across numerous industries and
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationAustralia: A Dynamic Environment for Conducting Clinical Trials
Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors
More informationENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ]
ENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ] BEING IN COMPLIANCE HAS NEVER BEEN MORE IMPORTANT Quality encompasses more than meeting regulatory requirements. It extends throughout your organization
More informationEFFICIENCY AND COST EFFECTIVENESS: 2015 DRIVERS FOR TECHNOLOGY SPEND
EFFICIENCY AND COST EFFECTIVENESS: 2015 DRIVERS FOR TECHNOLOGY SPEND 2 Over the past few years, capital market participants have invested heavily in technology and services to meet critical regulatory
More informationQuintiles Transnational Corporation Big is Beautiful
Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development
More informationGlobal Medical Device QA/RA Consulting
EmergoGroup.com Global Medical Device QA/RA Consulting More than 2,800 companies trust Emergo to achieve and maintain compliance with global medical device and IVD regulations. Core Areas of Expertise
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationArgus Ethylene Annual 2017
Argus Ethylene Annual 2017 Market Reporting Petrochemicals illuminating the markets Consulting Events Argus Ethylene Annual 2017 Summary Progress to the next peak of the economic cycle, now expected by
More informationANALYTICAL STANDARDS AND REAGENTS
ANALYTICAL STANDARDS AND REAGENTS productivity future growth globalization compliance Waters, the industry leader in liquid chromatography and mass spectrometry, understands that standards and reagents
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationCRO INDUSTRY GLOBAL COMPENSATION AND TURNOVER SURVEY
CRO INDUSTRY GLOBAL COMPENSATION AND TURNOVER SURVEY About the Survey The CRO Industry Global Compensation and Turnover Survey is entering its twentieth consecutive year. In 2017 it again had excellent
More informationSITSI Global Datamart
SITSI Global Datamart Local Software and IT Services Market Expertise on a Global Scale MARKET RESEARCH FROM PAC Every journey needs direction PAC s unrivaled breadth, quality and depth of market data
More informationAn Overview of ISO Anti-Bribery Management System Standard
An Overview of ISO 37001 Anti-Bribery Management System Standard Neill Stansbury Chair: ISO 37001 Project Committee Co-founder and Director: GIACC www.giaccentre.org 2017 GIACC 1 Bribery is a significant
More informationVELOPRESSO DELIVERY GUIDE
VELOPRESSO DELIVERY GUIDE We ship worldwide, and this document provides a guide to the options, cost and process of delivering a Velopresso coffee trike to you. Velopressos are sold in accord with Incoterms
More informationPyramid Research. Publisher Sample
Pyramid Research http://www.marketresearch.com/pyamidresearch-v4002/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationApplication from the World Federation of Chinese Medicine Societies for admission into official relations with WHO
EXECUTIVE BOARD EB136/NGO/6 136th session 6 November 2014 Provisional agenda item 13.3 Application from the World Federation of Chinese Medicine Societies for admission into official relations with WHO
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationDefinitive Merger Agreement Conference Call
Definitive Merger Agreement Conference Call Committed to providing products and services that ensure the best possible patient outcomes August 15, 2017 NASDAQ: SKLN Forward-Looking Statements This presentation
More informationCellular Therapy Products & NDC vs. ISBT128 Coding/Labeling
Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling William E. Janssen, Ph.D. Director, Cell Therapies Facility Moffitt Cancer Center Tampa, Florida What is ISBT 128? Information standard for blood,
More informationPESTICIDE SCREENING APPLICATION SOLUTION
PESTICIDE SCREENING APPLICATION SOLUTION The most innovative pesticide screening solution ever built for food, beverage, and water testing. As the global food trade continues to expand, so does the challenge
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationA shared global vision Helping you do business all over the world
Helping you do business all over the world Client Commitment Innovative Solutions Global Service Contents Client Commitment. Innovative Solutions. Global Service. 5 Why work with us? 6 Welcome to our world
More informationState of the Clinical Trials Industry
State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationGlobal Connections. Achieving Superior Local Results.
Global Connections. Achieving Superior Local Results. Welcome Global connections achieving superior clients, always a new practice to local results has been our tagline for develop. We are addressing today
More informationTO OUR SHAREHOLDERS: As 2001 drew to a close, Covance approached our five-year anniversary as a public company. We can
E A R LY D E V E L O P M E N T S E R V I C E S HIGHLIGHTS: Early Development Services contributed 39 percent of Covance s pro forma net revenues and more than half of our pro forma income from operations
More informationREGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)
REGULATION OF BIOLOGICAL PRODUCTS IN PERU Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) CONTENTS Introduction of DIGEMID Legal Bases of Biological Products
More informationCisco IT Data Center and Operations Control Center Tour
Cisco IT Data Center and Operations Control Center Tour Page 1 of 7 4 Root Cause Analysis and Change Management Root Cause Analysis Figure 1. Ian Reviewing Updates Ian: The incident management process
More informationCompliance speaks up. IPC Annual Survey of Compliance Officers across the financial markets ebook. Connecting opportunities.
Compliance speaks up IPC Annual Survey of Compliance Officers across the financial markets ebook www.ipc.com Connecting opportunities Table of Contents Introduction Compliance Raises Its Voice Regulatory
More informationDecision taken from September 2010 Four focus areas: megacities, informal sector, global recycling markets & international aid tools Members: Antonis
ISWA s Task Force on Globalization & Waste Management Decision taken from September 2010 Four focus areas: megacities, informal sector, global recycling markets & international aid tools Members: Antonis
More information[ VION IMS QTOF ] BEYOND RESOLUTION
[ VION IMS QTOF ] BEYOND RESOLUTION THE BENEFITS ARE CLEAR and routinely available, Complex samples give complex data with overlapping spectra and background interferences, making compound identification
More informationCharles River to Acquire WIL Research Charles River Laboratories International, Inc.
Charles River to Acquire WIL Research 2016 Charles River Laboratories International, Inc. Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities
More information2015 REGIONAL SENIOR EXECUTIVE REWARD SURVEY MERCER EXECUTIVE REMUNERATION GUIDES (MERG) CHINA, HONG KONG, INDIA, JAPAN AND SINGAPORE
2015 REGIONAL SENIOR EXECUTIVE REWARD SURVEY MERCER EXECUTIVE REMUNERATION GUIDES (MERG) CHINA, HONG KONG, INDIA, JAPAN AND SINGAPORE MERCER EXECUTIVE REMUNERATION GUIDES MERCER S NEW ASIA SENIOR EXECUTIVE
More informationuniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,
More informationWorking together to meet global energy challenges
Working together to meet global energy challenges Staff on loan From around the world From IEA and OECD member countries: Australia Austria Belgium Canada Chile Czech Republic Denmark Estonia Finland France
More informationInternationalisation Home versus host compensation approach at Reckitt Benckiser
Internationalisation Home versus host compensation approach at Reckitt Benckiser Internationalisation Home versus host compensation approach at Reckitt Benckiser With the economic downturn continuing worldwide,
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationhp hardware support onsite global next day response
hp care pack hp hardware support onsite technical data hp hardware support onsite global next day response service overview benefits to you service highlights HP s global next day response service provides
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationChallenging Stakeholders
5 Ways to Engage Challenging Stakeholders Graham Crawshaw MCIPS Director of Content December 2016 Not familiar with CASME? 40 benchmarking reports and procurement guides published each year A network of
More information2016 Global Manufacturing Competitiveness Index Report highlights
2016 Global Manufacturing Competitiveness Index Report highlights Years of successful collaboration exploring manufacturing competitiveness In collaboration with leading organizations, Deloitte has explored
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationEFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program. Copyright 2014 NUSAGE-PharmEng.
EFFECTIVE CLINICAL TRIALS NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE CLINICAL TRIALS Objective The intent
More informationThe European Medical Technology Industry. in figures / 2018
The European Medical Technology Industry in figures / 2018 Table of contents What is Medical Technology? 4 Innovation 10 Employment 14 Companies 18 Expenditure on Medical Technology 20 MedTech Market in
More informationYou don t have to be great to start, but you have to start to be great
You don t have to be great to start, but you have to start to be great Sports Marketing Agency Credentials Contents 01 Who are we 02 What do we do 03 What can we deliver 04 How do we do it 05 New opportunities
More informationGroup Daimler Assistance Systems for Safe Business
Group @ Daimler Assistance Systems for Safe Business Daimler AG, Group Daimler AG, Group 2 1. Integrity 2. Overview of @ Daimler 3. International 4. Execution in operational business 5. Takeaways Daimler
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationRaytheon Professional Services Training solutions that improve business performance
Raytheon Professional Services solutions that improve business performance Raytheon Professional Services is a global leader in training services and outsourcing. We improve clients business performance
More informationTime to assess your global mobility programme
Time to assess your global mobility programme GLOBAL MOBILITY PROGRAMME SCANNER As European companies strive to recover from a persistent recession, many seek to grow their business globally by using Mobility
More informationCALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY
CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY Executive Summary Prepared for Applied Biological Technologies Initiative Economic and Workforce Development Program California
More informationGlobal IT Procurement and Logistics. Simplifying the complex: an end-to-end IT supply chain solution
Global IT Procurement and Logistics Simplifying the complex: an end-to-end IT supply chain solution We make the complex simple Managing an international IT supply chain isn t an easy task, and comes with
More informationMERCER LIFE SCIENCES COMPENSATION SURVEY
HEALTH WEALTH CAREER MERCER LIFE SCIENCES COMPENSATION SURVEY ASIA PACIFIC MAKE SMART COMPENSATION DECISIONS BY JOINING THE MERCER TOTAL COMPENSATION SURVEY FOR THE LIFE SCIENCES INDUSTRY THE LIFE SCIENCES
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationMarine Harvest Intrafish Seafood Investor Forum, New York. 28 May 2015
Marine Harvest Intrafish Seafood Investor Forum, New York 28 May 2015 Forward looking statements This presentation may be deemed to include forward-looking statements, such as key determinants for future
More informationMicrosoft Dynamics CRM Online. Pricing & Licensing. Frequently Asked Questions
Microsoft Dynamics CRM Online Pricing & Licensing Frequently Asked Questions A frequently asked questions (FAQ) document on pricing & licensing for Microsoft Dynamics CRM Online. The document provides
More informationProduct Catalog # Description List Price (JPY) Primer Assays (desalted)
Assays and Controls Primer Assay Pricing Primer Assays (desalted) 10025636 Primer assay desalted, 200 reactions 16,000 (Wet-lab validated human, mouse, and rat) 10025637 Primer assay desalted, 1,000 reactions
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationCHINA. Australia - China Life Science Summit. . Bio & Pharma Logistics
CHINA. Bio & Pharma Logistics Andrew McDonald Operations Director, Asia Pacific Melbourne, Australia, 27th March 2013 Australia - China Life Science Summit Responsibilities Who takes responsibility on
More informationHello. a lot has changed since last year.
Moving forward a lot has changed since last year. Our name, for one. STR, Inc., STR Global Limited and STR Analytics are now united under one brand: STR. More than a brand, STR is the name that unites
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationCFO and Financial Executives
CFO and Financial Executives www.stantonchase.com Stanton Chase is a leader in executive search and leadership consulting with a global footprint, local expertise, and extensive experience across numerous
More informationDMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationsafetyiq: THE NEW DIMENSIONS OF SAFETY DISCOVER INTELLIGENT PROTECTION FOR MORE PRODUCTIVITY Forward-thinking safety products, systems and services
safetyiq: THE NEW DIMENSIONS OF SAFETY DISCOVER INTELLIGENT PROTECTION FOR MORE PRODUCTIVITY Forward-thinking safety products, systems and services safetyiq INTELLIGENT PROTECTION FOR MORE PRODUCTIVITY
More informationWinsoft Solutions L.L.C
Winsoft Solutions L.L.C Do i.t professionally 2002-2014 Add-Vantage Insurance Management System for TPA and insurance companies (Add-Vantage - IMS) DHA & HAAD compliant info@winsoftsolutions.net (+971)
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationThe Journey To Operational Intelligence
The Journey To Operational Intelligence Presented by Martin Otterson, Senior VP of Sales, Marketing and Industry 1 Learn Share Innovate This is your opportunity! 2 What would life be like without electricity?
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationInvestor Presentation: Phase II Data for LCP Tacro. March 3, 2008
Investor Presentation: Phase II Data for LCP Tacro March 3, 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may,
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More information4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015
4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015 VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP, BELGIUM 2 Join the 4 th one-day seminar to discuss
More informationGlobal Services and Capabilities
Global Services and Capabilities Our team of experts offers an unmatched combination of economic credentials, industry expertise, and testifying experience. GLOBAL SERVICES AND CAPABILITIES Insight in
More informationThe Most Advanced Critical Care Solutions. Anywhere, Everywhere.
The Most Advanced Critical Care Solutions. Anywhere, Everywhere. The GEM Family comprehensive critical care solutions in the lab and at the point-of-care. The GEM Family of critical care testing solutions
More information